Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05581823 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05581823 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT05581823, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
Interventions
- DRUG Carbamazepine
- DRUG Tavapadon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2023-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05581823
The ClinicalTrials.gov registry entry for NCT05581823 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbamazepine is the first listed.
NCT05581823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05581823 about?
NCT05581823 is a clinical study titled "Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants". The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
What is the current status of trial NCT05581823?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-10-19. Estimated completion is 2023-02-02.
What interventions are being tested in trial NCT05581823?
The interventions under investigation include: Carbamazepine (DRUG), Tavapadon (DRUG).
Who is sponsoring clinical trial NCT05581823?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.